Profound Medical Corp. Common Stock PROF
Analyst Ratings
- Consensus
- Buy — 1 Buy · 0 Hold · 0 Sell (1 analysts)
- Avg. Price Target
- $12.00 (+73.7% upside)
Key Stats
- Today's Range
- $6.04 – $6.92
- 50-Day Range
- $5.50 – $8.50
- 52-Week Range
- $3.76 – $8.95
- Volume
- 2.97 million shs
- Average Volume
- 224K shs
- Market Cap
- $207.55 million
- P/E Ratio
- 15.02
- Dividend Yield
- —
Valuation
- P/E Ratio
- 15.02
- Price / Book
- 4.17
- Price / Sales
- 10.87
Short Interest
- Short Interest
- 0.10%
- Days to Cover
- 2.10
Financials (TTM)
- Revenue
- $19.09 million
- Net Income
- $-32,745,000
- Net Margin
- -171.57%
- Return on Equity
- -65.74%
- Debt-to-Equity
- 0.09
About Profound Medical Corp. Common Stock
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
Related Stocks
Compare head-to-head: PROF vs SYK·PROF vs BSX·PROF vs RMD·PROF vs BAX
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.